Ralph Weichselbaum to Oncolytic Virotherapy
This is a "connection" page, showing publications Ralph Weichselbaum has written about Oncolytic Virotherapy.
Connection Strength
1.359
-
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov; 18(11):1098-102.
Score: 0.335
-
Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007 Oct; 3(5):545-56.
Score: 0.261
-
Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.
Score: 0.260
-
ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46.
Score: 0.245
-
Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006 Feb; 80(3):1110-20.
Score: 0.233
-
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
Score: 0.025